Age: 77.0
Sex: F
Vaccine: COVID19
Symptoms: Organising pneumonia, Oxygen saturation, Pruritus, Rash
Clinical narrative: shortness of breath; chest pain; hand was turning red; rash on the face,rash on  their back; itching both hands; cryptogenic organizing pneumonia; hypoxia; Inappropriate schedule of product administered; This spontaneous case was reported by a consumer and describes the occurrence of ORGANISING PNEUMONIA (cryptogenic organizing pneumonia), HYPOXIA (hypoxia), ERYTHEMA (hand was turning red), RASH (rash on the face,rash on  their back), PRURITUS (itching both hands), CHEST PAIN (chest pain) and DYSPNOEA (shortness of breath) in a 77-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 026B21A) and 042L20A)) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     Concurrent medical conditions included Drug hypersensitivity (hand were turned red and  developed a rash on the face, back and hands became itchy.). Concomitant products included LEVOFLOXACIN, OMEPRAZOLE, LEVOTHYROXINE, ESCITALOPRAM OXALATE (LEXAPRO) and AMLODIPINE for an unknown indication.   On 05-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 31-Mar-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 31-Mar-2021, the patient experienced INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Inappropriate schedule of product administered). On 22-Apr-2021, the patient experienced ORGANISING PNEUMONIA (cryptogenic organizing pneumonia) (seriousness criteria hospitalization prolonged and medically significant) and HYPOXIA (hypoxia) (seriousness criteria hospitalization prolonged and medically significant). On 16-Jun-2021, the patient experienced ERYTHEMA (hand was turning red) (seriousness criterion hospitalization prolonged), RASH (rash on the face,rash on  their back) (seriousness criterion hospitalization prolonged) and PRURITUS (itching both hands) (seriousness criterion hospitalization prolonged). On 20-Jun-2021, the patient experienced CHEST PAIN (chest pain) (seriousness criterion hospitalization prolonged). On 23-Jun-2021, the patient experienced DYSPNOEA (shortness of breath) (seriousness criterion hospitalization prolonged). On 31-Mar-2021, INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Inappropriate schedule of product administered) had resolved. At the time of the report, ORGANISING PNEUMONIA (cryptogenic organizing pneumonia) had not resolved and HYPOXIA (hypoxia), ERYTHEMA (hand was turning red), RASH (rash on the face,rash on  their back), PRURITUS (itching both hands), CHEST PAIN (chest pain) and DYSPNOEA (shortness of breath) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 22-Apr-2021, Oxygen saturation: decreased (Low) decreased.         Patient was still under doctors care, still has pneumonia and just got a heart monitor put on Sunday 19Sep2021.  Procedure heart monitor. Treatment information was not provided. On 22-Apr-2021, patient also mentions having reclast.  This case concerns a 77-year-old female patient with no reported medical history, who experienced the serious  unexpected event Organising pneumonia and hypoxia . The events occurred approximately two and a half months after the first dose and 22 days after the second and most recent dose of mRNA-1273 Moderna vaccine. Inappropriate schedule of vaccine administered was also captured as event. The benefit-risk relationship of mRNA-1273 Moderna vaccine is not affected by this report.   This case was linked to MOD-2021-325425 (Patient Link).; Sender's Comments: This case concerns a 77-year-old female patient with no reported medical history, who experienced the serious  unexpected event Organising pneumonia and hypoxia . The events occurred approximately two and a half months after the first dose and 22 days after the second and most recent dose of mRNA-1273 Moderna vaccine. Inappropriate schedule of vaccine administered was also captured as event. The benefit-risk relationship of mRNA-1273 Moderna vaccine is not affected by this report.